Solrun Melkorka Maggadottir
- PhD student; MD
HELSE SØR ØST
2017-to date: PhD student at the Department of Cellular Therapy/Faculty of Medicine University of Oslo, Norway.
2011-2014: Board Certified Allergist and Immunologist, University of Pennsylvania (UPENN), PA, USA.
2008-2011: Board Certified Pediatrician, University of Connecticut, Hartford, CT, USA.
1999-2005: MD, University of Iceland, Reykjavik, Iceland.
Development and clinical implementation of novel immunotherapies
- Translation/transition of pre-clinical data into clinical trials with focus on safety and efficacy
- Therapeutic TCR (T Cell Receptor) discovery, validation and translation into clinical trials
- Therapeutic CAR (Chimeric Antigen Receptor) discovery, validation and translation into clinical trials
- Improvement and advancement of clinical trials in cell-based therapy
2017-to date: PhD student, Department of Cellular Therapy, OUS-Radiumhospitalet, Norway
2014-2016: Immunology Specialist MD at the Department of Immunology, LSH University Hospital, Iceland.
2011-2014: Fellowship in Allergy/Immunology, The Children’s Hospital of Philadelphia, PA, USA
2008-2011: Pediatric Internship/Residency, Connecticut Children’s Medical Center, CT, USA
2006-2008: Critical Care/Anesthesiology and Pediatric Resident, LSH University Hospital, Iceland
2005-2006: Rotating Internship in Medicine, Surgery and Pediatrics, Landspitali (LSH) University Hospital, Iceland
- Oral presentation at AAAAI was selected as one of 9 abstracts from >1000 abstracts to be discussed at one of three press events during the meeting.
- Travel awards from AAAAI: 2011, 2013 and 2014. ACAAI: 2012 and 2013. ESID: 2012 and CIS: 2014.
- “Outstanding intern award” in pediatric residency in Connecticut, 2009.
- “Best research project of the year” in medical school, 2003.
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
Nat Commun, 14 (1), 3375
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
Front Oncol, 12, 1031232
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther, 29 (3), 1199-1213
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
Two Sides of the Same Coin: Pediatric-Onset and Adult-Onset Common Variable Immune Deficiency
J Clin Immunol, 37 (6), 592-602
Are genetic tests informative in predicting food allergy?
Curr Opin Allergy Clin Immunol, 16 (3), 257-64
Understanding the genetic and epigenetic basis of common variable immunodeficiency disorder through omics approaches
Biochim Biophys Acta, 1860 (11 Pt B), 2656-63
Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells
Nat Commun, 6, 6804
Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases
Nat Med, 21 (9), 1018-27
Genetic sharing and heritability of paediatric age of onset autoimmune diseases
Nat Commun, 6, 8442
Rare variants at 16p11.2 are associated with common variable immunodeficiency
J Allergy Clin Immunol, 135 (6), 1569-77
Resolution of acute IgE-mediated allergy with development of eosinophilic esophagitis triggered by the same food
J Allergy Clin Immunol, 133 (5), 1487-9, 1489.e1
The intersection of immune deficiency and autoimmunity
Curr Opin Rheumatol, 26 (5), 570-8
The ex vivo induction of human CD103⁺ CD25hi Foxp3⁺ CD4⁺ and CD8⁺ Tregs is IL-2 and TGF-β1 dependent
Scand J Immunol, 77 (2), 125-34
The diverse clinical features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome)
J Allergy Clin Immunol Pract, 1 (6), 589-94
Anti-CD28-induced co-stimulation and TCR avidity regulates the differential effect of TGF-beta1 on CD4+ and CD8+ naïve human T-cells
Int Immunol, 17 (1), 35-44